You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 10,959,947

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,959,947 protect, and when does it expire?

Patent 10,959,947 protects FIRVANQ KIT and is included in one NDA.

This patent has nine patent family members in seven countries.

Summary for Patent: 10,959,947

Patent landscape, scope, and claims:

Title:	Composition and method for vancomycin oral liquid
Abstract:	The invention relates to stable vancomycin hydrochloride powder for oral liquid formulations. Also provided herein are methods of using vancomycin oral liquid formulations for the treatment of certain diseases such as Clostridium difficile pseudomembranous colitis and Staphylococcal enterocolitis as well as kits and related products thereof.
Inventor(s):	Muni; Indu (North Reading, MA), Mione; Peter (Malden, MA), Gandhi; Anisa (Medford, MA), LeChiara; Cristina (Saugus, MA)
Assignee:	Azurity Pharmaceuticals, Inc. (Woburn, MA)
Application Number:	16/892,421
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Compound; Dosage form;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 10,959,947

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Azurity	FIRVANQ KIT	vancomycin hydrochloride	FOR SOLUTION;ORAL	208910-001	Jan 26, 2018	AB	RX	Yes	Yes	10,959,947	⤷ Subscribe	Y			TREATMENT OF STAPHYLOCOCCAL ENTEROCOLITIS	⤷ Subscribe
Azurity	FIRVANQ KIT	vancomycin hydrochloride	FOR SOLUTION;ORAL	208910-001	Jan 26, 2018	AB	RX	Yes	Yes	10,959,947	⤷ Subscribe	Y			TREATMENT OF C. DIFFICILE-ASSOCIATED DIARRHEA	⤷ Subscribe
Azurity	FIRVANQ KIT	vancomycin hydrochloride	FOR SOLUTION;ORAL	208910-002	Jan 26, 2018	AB	RX	Yes	Yes	10,959,947	⤷ Subscribe	Y			TREATMENT OF C. DIFFICILE-ASSOCIATED DIARRHEA	⤷ Subscribe
Azurity	FIRVANQ KIT	vancomycin hydrochloride	FOR SOLUTION;ORAL	208910-002	Jan 26, 2018	AB	RX	Yes	Yes	10,959,947	⤷ Subscribe	Y			TREATMENT OF STAPHYLOCOCCAL ENTEROCOLITIS	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 10,959,947

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015229069	⤷ Subscribe
Canada	2941867	⤷ Subscribe
China	106573037	⤷ Subscribe
European Patent Office	3145527	⤷ Subscribe
European Patent Office	4000628	⤷ Subscribe
Spain	2903419	⤷ Subscribe
Japan	2017508807	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.